Table 1 Most targeted antigen in clinical trials in solid tumor CAR T cell therapy
From: CAR T cells in solid tumors: challenges and opportunities
Antigen | Cancer | Phase | ID |
|---|---|---|---|
EGFR | Lung, liver, stomach | Phase 1/2 | NCT03179007, NCT03525782 |
HER2 | Central nervous system tumor, pediatric glioma | Phase 1 | NCT03500991 |
EGFR806 | Central nervous system tumor, pediatric glioma | Phase 1 | NCT03179012 |
Mesothelin | Ovarian, cervical, pancreatic, lung | Phase 1/2 | NCT01583686 |
PSCA | Lung | Phase 1 | NCT03198052 |
MUC1 | Advanced solid tumors, lung | Phase 1/2 | NCT03179007, NCT03525782 |
Claudin 18.2 | Advanced solid tumor | Phase 1 | NCT03874897 |
EpCAM | Colon, pancreatic, prostate, gastric, liver | Phase 1/2 | NCT03013712 |
GD2 | Brain | Phase 1 | NCT04099797 |
VEGFR2 | Melanoma, brain | Phase 1 | NCT01218867 |
AFP | Hepatocellular carcinoma liver cancer | Phase 1 | NCT03349255 |
Nectin4/FAP | Nectin4-positive advanced malignant solid tumor | Phase 1 | NCT03932565 |
CEA | Lung, colorectal, gastric, breast, pancreatic cancer | Phase 1 | NCT02349724 |
Lewis Y | Advanced cancer | Phase 1 | NCT03851146 |
Glypican-3 | Liver | Phase 1 | NCT02932956 |
EGFRIII | Glioblastoma and brain tumor | Phase 1 | NCT01454596 |
IL-13Rα2 | Glioblastoma | Phase 1 | NCT02208362 |
CD171 | Neuroblastoma | Phase 1 | NCT02311621 |
MUC16 | Ovarian | Phase 1 | NCT02311621 |
PSMA | Prostate | Phase 1 | NCT01140373 |
AFP | Hepatocellular carcinoma, liver | Phase 1 | NCT03349255 |
AXL | Renal | Phase 1 | NCT03393936 |
CD20 | Melanoma | Phase 1 | NCT03893019 |
CD80/86 | Lung | Phase 1 | NCT03198052 |
c-MET | Breast, hepatocellular | Phase 1 | NCT03060356, NCT03638206 |
DLL-3 | Lung | Phase 1 | NCT03392064 |
DR5 | Hepatoma | Phase 1 | NCT03638206 |
EpHA2 | Glioma | Phase 1 | NCT02575261 |
FR-α | Ovarian | Phase 1 | NCT00019136 |
gp100 | Melanoma | Phase 1 | NCT03649529 |
MAGE-A1/3/4 | Lung | Phase 1 | NCT03356808, NCT03535246 |
LMP1 | Nasopharyngeal | Phase 1 | NCT02980315 |